Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

The antibacterial effect of human adipose-derived stem cells on LL-37-resistant bacteria.

Afzal Haghjoo P., Mojtahedi A., Ansar MM., Ansar MM., Danesh Mobarhan S.

Laboratory Study, published in PLoS One (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
PLoS One (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41105689
PMCID
PMC12533887
DOI
10.1371/journal.pone.0333647

Abstract (original English)

Human adipose-derived stem cells (hADSCs) exhibit antibacterial properties, but their effectiveness against bacteria resistant to LL-37- a natural human antimicrobial peptide important in the immune defense- is not fully understood. Some bacteria have evolved mechanisms to evade the antimicrobial effects of LL-37. We aimed to investigate the antibacterial efficacy of hADSCs against Pseudomonas aeruginosa, Proteus mirabilis, and methicillin-resistant Staphylococcus aureus (MRSA), focusing on the antimicrobial peptide LL-37. hADSCs were isolated from human adipose tissue, identified by flow cytometry and differentiation assays, and divided into three groups: unstimulated, stimulated with interferon-gamma (IFN-γ; 100 ng/mL) or Escherichia coli (300 CFU). LL-37 gene expression was measured by qPCR after 6 hours in the E. coli stimulated group. LL-37 peptide levels were quantified by ELISA in conditioned media from unstimulated, IFN-γ stimulated cells, both before and after incubation with pathogens (300 CFU). Antibacterial activity was assessed by colony counting incubation following incubation of conditioned media with bacteria. Conditioned media from both unstimulated and stimulated hADSCs significantly inhibited growth of all three pathogens (P < 0.05), with highest efficacy against P. aeruginosa (86.4% inhibition), followed by MRSA (74%) and P. mirabilis (63%). LL-37 gene expre

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansCathelicidinsStem CellsAdipose TissueAntimicrobial Cationic PeptidesPseudomonas aeruginosaMethicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsProteus mirabilisEscherichia coli

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.